Interestingly, the dock score of Cinnamaldehyde was comparable to orlistat with both receptor proteins, AMPK and NF-kB, indicating that Cinnamaldehyde can be a promising molecule for treating obesity-associated nephropathy. This evidence concerns the gene NFKB1 and obesity due to melanocortin 4 receptor deficiency.